scholarly journals Caralluma Acutangula Prevents Body Weight Gain in Rats Feed on Hyperlipidic Diet

2018 ◽  
Vol 75 (2) ◽  
pp. 168
Author(s):  
Pare DRAMANE ◽  
Hilou ADAMA ◽  
Adrian POTÂRNICHE ◽  
Mabozou KPEMISSI ◽  
Orsolya SÁRPATAKI ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Body Weight Gain ◽  
Body Weight Loss ◽  
Treated Group ◽  
Total Phenolic ◽  
Control Group ◽  
Hyperlipidic Diet

Caralluma acutangula (Decne.) (CA) (Asclepiadaceae) is a medicinal plant traditionally used in Burkina Faso for the management of weight. The aim of this study was to evaluate the effect of extract of CA on body weight, food intake, blood biochemistry parameters on experimental obesity rat model. One group received CA 400 mg/kg b.w. per day and was fed on hyperlipidic diet (HD), while the control group received HD only for three weeks long. The phytochemical investigation of extract showed a high total phenolic content (36.21±1.36 mg GAE/100mg of extract) and total flavonoids (4.98 ±0.31 QE/100 mg of extract). In the end, CA-HD treated group had a body weight loss of 2%, compared to HD group who presented a body weight gain of 15%. The CA-HD treated group showed also a lower levels of plasma triglyceride (136.57±13.82 mg/dL) and glycemia (187.74±31.16 mg/dL) compared to HD (206.02±23.82 and respectively 230.96±79.07 mg/dL) (p<0.05). CA extract also showed a good anti-oxidant activity in vivo (effect on antioxydant enzyme (MDA, GPX, SOD) and in vitro (inhibition of DPPH radical, ferric ion reduction). This study showed that CA is a potential natural remedy for the control of body weight and alleviation of obesity related disease.

scholarly journals Anti-Obesity and Anti-Adipogenic Effects of Chitosan Oligosaccharide (GO2KA1) in SD Rats and in 3T3-L1 Preadipocytes Models

Molecules ◽  
2021 ◽  
Vol 26 (2) ◽  
pp. 331
Author(s):  
Jung-Yun Lee ◽  
Tae Yang Kim ◽  
Hanna Kang ◽  
Jungbae Oh ◽  
Joo Woong Park ◽  
...  
Keyword(s):  
Gene Expression ◽  
Body Weight ◽  
Density Lipoprotein ◽  
Treated Group ◽  
Control Group ◽  
Chitosan Oligosaccharide ◽  
Sd Rats ◽  
Adipogenic Gene

Excess body weight is a major risk factor for type 2 diabetes (T2D) and associated metabolic complications, and weight loss has been shown to improve glycemic control and decrease morbidity and mortality in T2D patients. Weight-loss strategies using dietary interventions produce a significant decrease in diabetes-related metabolic disturbance. We have previously reported that the supplementation of low molecular chitosan oligosaccharide (GO2KA1) significantly inhibited blood glucose levels in both animals and humans. However, the effect of GO2KA1 on obesity still remains unclear. The aim of the study was to evaluate the anti-obesity effect of GO2KA1 on lipid accumulation and adipogenic gene expression using 3T3-L1 adipocytes in vitro and plasma lipid profiles using a Sprague-Dawley (SD) rat model. Murine 3T3-L1 preadipocytes were stimulated to differentiate under the adipogenic stimulation in the presence and absence of varying concentrations of GO2KA1. Adipocyte differentiation was confirmed by Oil Red O staining of lipids and the expression of adipogenic gene expression. Compared to control group, the cells treated with GO2KA1 significantly decreased in intracellular lipid accumulation with concomitant decreases in the expression of key transcription factors, peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT/enhancer-binding protein alpha (CEBP/α). Consistently, the mRNA expression of downstream adipogenic target genes such as fatty acid binding protein 4 (FABP4), fatty acid synthase (FAS), were significantly lower in the GO2KA1-treated group than in the control group. In vivo, male SD rats were fed a high fat diet (HFD) for 6 weeks to induced obesity, followed by oral administration of GO2KA1 at 0.1 g/kg/body weight or vehicle control in HFD. We assessed body weight, food intake, plasma lipids, levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) for liver function, and serum level of adiponectin, a marker for obesity-mediated metabolic syndrome. Compared to control group GO2KA1 significantly suppressed body weight gain (185.8 ± 8.8 g vs. 211.6 ± 20.1 g, p < 0.05) with no significant difference in food intake. The serum total cholesterol, triglyceride, and low-density lipoprotein (LDL) levels were significantly lower in the GO2KA1-treated group than in the control group, whereas the high-density lipoprotein (HDL) level was higher in the GO2KA1 group. The GO2KA1-treated group also showed a significant reduction in ALT and AST levels compared to the control. Moreover, serum adiponectin levels were significantly 1.5-folder higher than the control group. These in vivo and in vitro findings suggest that dietary supplementation of GO2KA1 may prevent diet-induced weight gain and the anti-obesity effect is mediated in part by inhibiting adipogenesis and increasing adiponectin level.

scholarly journals Bauhiniastatin-1 alleviates diet induced obesity and lipid accumulation through modulating PPAR-γ/AMPK expressions: In-vitro, in-vivo and in-silico studies.

2021 ◽  
Author(s):  
Karunakaran Reddy Sankaran ◽  
Lokanatha Oruganti ◽  
Muni Swamy Ganjayi ◽  
Venkataramaiah Chintha ◽  
Muni Kesavulu Muppuru ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Western Blot ◽  
Blot Analysis ◽  
Body Weight Gain ◽  
Liver Lipid ◽  
Ppar Γ ◽  
Diet Induced Obesity

Abstract Background: Consumption of energy dense foods and sedentary lifestyles have led to high prevalence of obesity and associated disorders. Intensive research efforts have focussed to develop effective alternative therapeutics from plant sources. Bauhiniastatins have been reported to possess antineoplastic activity. In the present study, Bauhiniastatin-1 (BSTN1) was isolated and purified from Bauhinia purpurea and evaluated for its therapeutic efficacy against adipogenesis and obesity using high fat diet (HFD)-induced obese rodent model and 3T3-L1 cells.Methods: We performed in-vitro experiments like MTT assay, Oil Red O (ORO) stain, cellular lipid content, glycerol release and RT-PCR analysis in 3T3-L1 cells. In-vivo parameters like body weight gain, body composition, plasma adipokines, serum & liver lipid profiles, liver marker enzymes, western blot analysis and histopathological examination were conducted in rat model. In addition, molecular docking studies were also performed to understand interaction of BSTN1 with peroxisome proliferator-activated gamma receptor (PPAR-γ) and AMP-activated protein kinase (AMPK) which supported our experimental results.Results: BSTN1 at 20 μM significantly (p<0.001) inhibited cell differentiation and lipid accumulation of 3T3-L1 adipocytes. Mechanistic studies showed that mRNA expression of key adipogenic markers, PPAR-γ, fatty acid synthase (FAS) and sterol-regulatory element-binding protein-1 (SREBP1) were down-regulated while AMPK was up-regulated by BSTN1. Oral administration of BSTN1 (5 mg/kg. b.wt.) to HFD-induced obese rats substantially decreased body weight gain, fat mass, serum and liver lipid levels and promoted integrity of hepatic and adipose tissue architecture compared to HFD-control rats. In BSTN1 administered groups, decreased serum aspartate transaminase (AST) and alanine aminotransferase (ALT) levels, decreased plasma leptin but increased adiponectin levels were noted. Western blot analysis of adipose and hepatic tissues collected from BSTN1 treated rats showed decreased expression level of PPAR-γ but increase in AMPK expression relative to the untreated group. In-silico studies showed strong binding interactions of BSTN1 against PPAR-γ and AMPK, the key molecules of adipogenesis and obesity.Conclusions: Taken together, the results suggest that BSTN1 could be promising molecule for the treatment of diet-induced obesity and non-alcoholic fatty liver disease (NAFLD).

scholarly journals GIP receptor antagonist treatment causes weight loss in ovariectomized high fat diet-fed mice

2021 ◽  
Author(s):  
Geke Aline Boer ◽  
Jenna Hunt ◽  
Maria Gabe ◽  
Johanne Windeløv ◽  
Alexander Sparre-Ulricht ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
High Fat Diet ◽  
Body Weight Gain ◽  
Pharmacokinetic Profile ◽  
High Fat ◽  
Ovariectomized Mice ◽  
Gip Receptor

Background and purpose The incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), secreted by the enteroendocrine K-cells in the proximal intestine, may regulate lipid metabolism and adiposity but its exact role in these processes is unclear. Experimental approach We characterized in vitro and in vivo antagonistic properties of a novel GIP analogue, mGIPAnt-1. We further assessed the in vivo pharmacokinetic profile of this antagonist, as well as its ability to affect high-fat diet (HFD)-induced body weight gain in ovariectomized mice during an 8-week treatment period. Key results mGIPAnt-1 showed competitive antagonistic properties to the GIP receptor (GIPR) in vitro as it inhibited GIP-induced cAMP accumulation in COS-7 cells. Furthermore, mGIPAnt-1 was capable of inhibiting GIP-induced glucoregulatory and insulinotropic effects in vivo and has a favourable pharmacokinetic profile with a half-life of 7.2 hours in C57Bl6 female mice. Finally, sub-chronic treatment with mGIPAnt-1 in ovariectomized HFD mice resulted in a reduction of body weight and fat mass. Conclusion and Implications mGIPAnt-1 successfully inhibited acute GIP-induced effects in vitro and in vivo and sub-chronically induces resistance to HFD-induced weight gain in ovariectomized mice. Our results support the development of GIP antagonists for the therapy of obesity.

scholarly journals Effect of spirulina (Spirulina platensis) and vitamin E on arsenic induced toxicity in Quail

2020 ◽  
Vol 6 (1) ◽  
pp. 93-98
Author(s):  
Most Fayza Khatun ◽  
Md Mahmudul Hasan ◽  
Rakibul Islam ◽  
Sumon Sarkar ◽  
Md Anowarul Haque
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Vitamin E ◽  
Arsenic Trioxide ◽  
Spirulina Platensis ◽  
Body Weight Gain ◽  
Treated Group ◽  
Control Group ◽  
Arsenic Toxicity ◽  
Histopathological Changes

Chronic arsenic toxicity is a severe disease in men and animals which occurs severely in Bangladesh. Arsenic (As) contamination in ground water used in drinking is the major concern because arsenic is present in human and animal food chain. This work was done in quails with a view to observing the efficacy of spirulina (Spirulina platensis) and vitamin E for prevention of arsenic toxicity. 60 quails were used in this study and animals were divided into control group (T0), arsenic treated group (T1), arsenic plus spirulina treated group (T2) and arsenic plus vitamin E treated group (T3). Each group consists of 15 quails. Quails of T0 group were given normal feed and water and kept as control. Quails of T1, T2 and T3 were given 100 mg arsenic trioxide/L drinking water daily for 30 days. In addition to arsenic trioxide quails of group T2 and T3 were simultaneously fed with spirulina @ 1 gm/kg feed and vitamin E @ 400 mg /kg body weight up to 30 days respectively. Five quails from each group (T0, T1, T2 and T3) were sacrificed at 15 days interval in order to determine haematological parameters. Result showed that in group T1, body weight gain was minimum, whereas in group T2 and T3 the body weight gain in quails were better. Reduction of TEC and Hb values were observed in arsenic treated group T1. Whereas in rest groups the TEC and Hb values were comparatively higher than arsenic treated group. Noticeable change observed in liver and kindey of arsenic treated group in compare to the control group. Histopathological changes also observed in liver and kindey of arsenic treated group in compare to the control group. In conclusion, spirulina and vitamin E have significant effect on body weight, hematological and postmortem and histopathological changes. Asian J. Med. Biol. Res. March 2020, 6(1): 93-98

scholarly journals ​Therapeutic Efficacy of Ethanolic Extract of Curcuma longa and its Component, Curcumin against Experimental Cryptosporidiosis in Mice

2021 ◽  
Author(s):  
Alveena Ganai ◽  
Anish Yadav ◽  
Rajesh Katoch ◽  
Dibyendu Chakraborty ◽  
Pawan Kumar Verma ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Body Weight Gain ◽  
Curcuma Longa ◽  
Ethanolic Extract ◽  
Control Group ◽  
Rrna Gene ◽  
Histopathological Changes ◽  
Group I

Background: Cryptosporidiosis caused by Cryptosporidium spp. is a zoonotic disease and is the most prevalent pathogens worldwide and leads to severe diarrhoeal diseases and affects the immunological status of the individual. Thus, the study was undertaken to examine the anti-cryptosporidial efficacy of curcumin in comparison with ethanolic extract of curcuma longa in immunocompromised mice infected with oocysts isolated from cattle calves of Jammu region and identified as Cryptosporidium parvum using nested PCR on small subunit ribosomal ribonucleic acid (SSU rRNA) gene. Methods: Two hundred female Swiss albino mice were equally divided into ten groups. Group I were kept as a healthy control, group II were immunocompromised, group III were immunocompromised and infected, group IV animals were immunocompromised, infected and treated orally with nitazoxanide. Animals in groups V to VII were immunocompromised, infected and treated with ethanolic extract of C. longa @ 4, 6 and 8 mg/kg/day/os respectively whereas groups VIII to X were immunocompromised, infected and treated with pure salt of curcumin @ 4, 6 and 8 mg/kg/day/os respectively for 5 successive days. Thus, mean oocysts per gram faeces, body weight gain and histopathological changes were measured in different groups. Result: Administration of curcumin as a therapeutic agent @ 8 mg/kg body weight for five days resulted in higher percent mean oocyst reduction of 74.03% and improved body weight gain in experimentally infected mice. Histopathological changes showed that treatment with oral curcumin (group X) in animals had minimal and improved intestinal lesions as compared to animals treated with C. longa (group VII). Altogether, curcumin showed promising anticryptosporidial effects under in vivo conditions and deserves further exploration.

Selection, characterisation and evaluation of potential probiotic Lactobacillus spp. isolated from poultry droppings

2016 ◽  
Vol 7 (1) ◽  
pp. 35-44 ◽  
Author(s):  
S. Asghar ◽  
M. Arif ◽  
M. Nawaz ◽  
K. Muhammad ◽  
M.A. Ali ◽  
...  
Keyword(s):  
Immune Response ◽  
Body Weight ◽  
Weight Gain ◽  
Body Weight Gain ◽  
Negative Control ◽  
The Body ◽  
Control Group ◽  
Rrna Gene ◽  
Poultry Droppings

Aim of the present study was to characterise and evaluate probiotic potential of lactobacilli isolated from indigenous poultry. Lactobacilli were isolated from poultry droppings and identified by genus specific polymerase chain reaction and 16S rRNA gene sequencing. Isolates were characterised in vitro by their ability to tolerate low pH and bile salts, phytase activity, antimicrobial activity, antibiotic susceptibility profile, and autoaggregation and coaggregation with poultry gut pathogens. In vivo evaluation of selected isolates was done by their effect on the body weight gain and immune response of broiler chicks. Total of 90, one-day old chicks, were randomly divided in 9 groups and given selected lactobacilli alone and in combinations (108 cfu/bird, daily) from day 7 to day 35. Body weight gain and humoral immune response to New Castle Disease Virus (NDV) vaccine were determined weekly. Three lactobacilli isolates (SMP52, SMP64 and SMP70) were selected as potentially probiotic bacteria on the basis of in vitro characterisation and identified as Lactobacillus crispatus, Lactobacillus casei and L. crispatus, respectively. Chicks supplemented with ‘SMP52’, ‘SMP64’, ‘SMP70’ and ‘SMP64+SMP70’ and a commercial probiotic product (Protexin) showed significantly higher mean weight gain per bird (1,584±35.2, 1,629±30.6, 1,668±34.7, 1,619±29.5 and 1,576±31.7 g/bird, respectively) as compared to negative control group (1,394±26.7 g/bird), on day 35. SMP 70 also showed significantly higher geometric mean titre against NDV vaccine at day 21 as compared to negative control. It is concluded that L. crispatus SMP52, L. casei SMP64 and L. crispatus SMP70 are potential probiotic candidates which alone or in different combinations may increase body weight of broilers.

scholarly journals Comparative efficacy of korolla (Momordica charantia) extract and Ivermec® pour on with their effects on certain blood parameters and body weight gain in indigenous chicken infected with Ascaridia galli

1970 ◽  
Vol 6 (2) ◽  
pp. 153-158 ◽  
Author(s):  
HM Shahadat ◽  
M Mostofa ◽  
MAA Mamum ◽  
ME Hoque ◽  
MA Awal
Keyword(s):  
Body Weight ◽  
Aqueous Extract ◽  
Body Weight Gain ◽  
Momordica Charantia ◽  
Control Group ◽  
Ascaridia Galli ◽  
Indigenous Chicken ◽  
Group B

Comparative anthelmintics efficacy of whole korolla fruit (Momordica charantia) extract and ivermec® pour on was evaluated in vitro and in vivo on adult Ascaridia galli of indigenous chicken. The total trial chickens (60) were divided equally into 3 groups; group A as control, group B treated with ivermec® pour on @ 500 μg/kg bwt by dropper through skin absorption for single dose and group C treated with 3% aqueous extract of korolla. Freshly prepared aqueous extract of the korolla fruit was performed as wormicidal properties against adult A. galli on in vitro and in vivo study. 3% aqueous extract of korolla fruit was treated as higher efficacy against A. galli. The live body weight was increased in chicken after treatment in group B and C respectively but in control group body weight was slowly decreased. TEC (million/cu mm), Hb (gm %) and PCV (%30 minutes) were increased significantly in chickens of treated groups whereas ESR was increased in control groups. Key words: Anthelmintics efficacy, korolla, Ivermec® pour on, Ascaridia galli, indigenous chicken, haematological parameters  doi: 10.3329/bjvm.v6i2.2328 Bangl. J. Vet. Med. (2008). 6 (2): 153-158   

scholarly journals N-acetylcysteine+nimesulide: An association strategy aiming to prevent nimesulide-induced hepatotoxicity

2021 ◽  
Vol 19 (2) ◽  
pp. 91-99
Author(s):  
Amanda G. Elias ◽  
Julia S. da Silva ◽  
Rafaela L. Klein ◽  
Francieli U. I. Amaral ◽  
Marcelo D. Arbo ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Cell Model ◽  
Body Weight Gain ◽  
The Body ◽  
Relative Mass ◽  
Male Wistar Rats ◽  
Control Body

Introduction: Nimesulide is a potent anti-inflammatorywith rapid and long-lasting effects, but also with a high riskof hepatotoxicity. Objective: This work aimed to preventnimesulide-induced hepatotoxicity through the associationof nimesulide with a hepatoprotective agent. Materials andMethods: First, we tested three hepatoprotective agents:N-acetylcysteine, L-carnitine, and Gingko biloba extract inan in vitro hepatic cell model. Both N-acetylcysteine and G.biloba showed promisor results. We selected N-acetylcysteineto continue the studies in an animal model. In vivo study wasperformed using male Wistar rats divided in 4 groups: control,nimesulide (100mg/kg/day), nimesulide (100mg/kg/day) +N-acetylcysteine (100mg/kg/day) and N-acetylcysteine alone(100mg/kg/day). Treatments were given by gavage, daily, for15 days. Results: Animals receiving nimesulide alone showedlower body weight gain compared to control. Body weightgain in the nimesulide + N-acetylcysteine group was higherthan nimesulide alone, evidencing lower toxicity. However,the body weight gain of the nimesulide + N-acetylcysteinegroup was still lower than the control animals. Animals treatedwith nimesulide alone presented an increased relative mass ofheart, liver, and spleen and significant hepatic damage seen inmicroscopy when compared to other groups. N-acetylcysteineco-administered with nimesulide prevented the increasedheart mass, but the same was not true with liver and spleen.Conclusions: This work evidence partial protection elicitedby the association of N-acetylcysteine and nimesulide againstnimesulide-induced hepatotoxicity.

Genistein and daidzein decrease food intake and body weight gain in mice, and alter LXR signaling in vivo and in vitro

2018 ◽  
Vol 9 (12) ◽  
pp. 6257-6267 ◽  
Author(s):  
Ting Luo ◽  
Omar Miranda-Garcia ◽  
Geoff Sasaki ◽  
Jinling Wang ◽  
Neil F. Shay
Keyword(s):  
Metabolic Syndrome ◽  
Body Weight ◽  
Weight Gain ◽  
Food Intake ◽  
Glucose Metabolism ◽  
Body Weight Gain ◽  
Differential Effects ◽  
Decrease Food Intake

Genistein and daidzein decrease mice food intake, ameliorate symptoms of metabolic syndrome, including decreasing body weight gain, and improving glucose metabolism, and appear to produce differential effects, possibly via the regulation of LXR-mediated pathways.

scholarly journals Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Elizabeth A. Killion ◽  
Michelle Chen ◽  
James R. Falsey ◽  
Glenn Sivits ◽  
Todd Hager ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Body Weight Gain ◽  
Preclinical Models ◽  
Prevent Weight Gain ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Abstract Antagonism or agonism of the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) prevents weight gain and leads to dramatic weight loss in combination with glucagon-like peptide-1 receptor agonists in preclinical models. Based on the genetic evidence supporting GIPR antagonism, we previously developed a mouse anti-murine GIPR antibody (muGIPR-Ab) that protected diet-induced obese (DIO) mice against body weight gain and improved multiple metabolic parameters. This work reconciles the similar preclinical body weight effects of GIPR antagonists and agonists in vivo, and here we show that chronic GIPR agonism desensitizes GIPR activity in primary adipocytes, both differentiated in vitro and adipose tissue in vivo, and functions like a GIPR antagonist. Additionally, GIPR activity in adipocytes is partially responsible for muGIPR-Ab to prevent weight gain in DIO mice, demonstrating a role of adipocyte GIPR in the regulation of adiposity in vivo.

Sign in / Sign up

Export Citation Format

Share Document